| Identification | Back Directory | [Name]
Sipoglitazar | [CAS]
342026-92-0 | [Synonyms]
TAK654
TAK-654
TAK 654
CS-1568
Sipoglitazar
3-[3-Ethoxy-1-[4-(2-phenyl-4-thiazolylMethoxy)benzyl]-1H-pyrazol-4-yl]propionic Acid
3-Ethoxy-1-[[4-[(2-phenyl-4-thiazolyl)Methoxy]phenyl]Methyl]-1H-pyrazole-4-propanoic Acid
3-[3-Ethoxy-1-[4-[(2-phenyl-1,3-thiazol-4-yl)Methoxy]benzyl]-1H-pyrazol-4-yl]propionic Acid
1H-Pyrazole-4-propanoic acid, 3-ethoxy-1-[[4-[(2-phenyl-4-thiazolyl)methoxy]phenyl]methyl]- | [Molecular Formula]
C25H25N3O4S | [MDL Number]
MFCD23704881 | [MOL File]
342026-92-0.mol | [Molecular Weight]
463.549 |
| Chemical Properties | Back Directory | [Melting point ]
111-112oC | [storage temp. ]
-20°C Freezer | [solubility ]
Chloroform (Slightly), Methanol (Slightly) | [form ]
Solid | [color ]
White |
| Hazard Information | Back Directory | [Uses]
Sipoglitazar is a novel antidiabetic agent. Sipoglitazar displays triple agonistic activities on the human peroxisome proliferator-activated receptors, hPPAR-γ, -α, and -δ. |
|
| Company Name: |
Cckinase, Inc.
|
| Tel: |
+1 (732)236-3202 |
| Website: |
www.cckinase.com |
|